These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

390 related articles for article (PubMed ID: 34028657)

  • 1. A Bioinformatics Investigation into the Pharmacological Mechanisms of Sodium-Glucose Co-transporter 2 Inhibitors in Diabetes Mellitus and Heart Failure Based on Network Pharmacology.
    Mai Z; Li H; Chen G; Chen E; Liu L; Lun Z; Lai W; Zhou C; Yu S; Liu J; Chen S; Chen J; Liu Y
    Cardiovasc Drugs Ther; 2022 Aug; 36(4):713-726. PubMed ID: 34028657
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanisms of Cardiorenal Protection With SGLT2 Inhibitors in Patients With T2DM Based on Network Pharmacology.
    Wang A; Li Z; Zhuo S; Gao F; Zhang H; Zhang Z; Ren G; Ma X
    Front Cardiovasc Med; 2022; 9():857952. PubMed ID: 35677689
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exploring therapeutic targets and molecular mechanisms for treating diabetes mellitus-associated heart failure with Qishen Yiqi dropping pills: A network pharmacology and bioinformatics approach.
    Ma Y; Lai J; Chen Z; Wan Q; Shi X; Zhou H; Li J; Yang Z; Wu J
    Medicine (Baltimore); 2024 Aug; 103(31):e39104. PubMed ID: 39093800
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stabilization of kidney function and reduction in heart failure events with sodium-glucose co-transporter 2 inhibitors: A meta-analysis and meta-regression analysis.
    Keidai Y; Yoshiji S; Hasebe M; Minamino H; Murakami T; Tanaka D; Fujita Y; Inagaki N
    Diabetes Obes Metab; 2023 Sep; 25(9):2505-2513. PubMed ID: 37217461
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardio-renal benefits of sodium-glucose co-transporter 2 inhibitors in heart failure with reduced ejection fraction: mechanisms and clinical evidence.
    Aguilar-Gallardo JS; Correa A; Contreras JP
    Eur Heart J Cardiovasc Pharmacother; 2022 May; 8(3):311-321. PubMed ID: 34264341
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of sodium glucose co-transporter 2 inhibitors in patients with heart failure: an elusive mechanism.
    Imran H; Nester W; Elgendy IY; Saad M
    Ann Med; 2020 Aug; 52(5):178-190. PubMed ID: 32393068
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardio-Protective Effects of Sodium-Glucose Co-Transporter 2 Inhibitors: Focus on Heart Failure.
    Karangelis D; Mazer CD; Stakos D; Tzifa A; Loggos S; Verma S; Mitropoulos F
    Curr Pharm Des; 2021; 27(8):1051-1060. PubMed ID: 33143620
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of sodium-glucose co-transporter 2 protein inhibitors in heart failure: more than an antidiabetic drug?
    Savarimuthu S; Harky A
    Expert Opin Pharmacother; 2022 Feb; 23(3):377-386. PubMed ID: 34713764
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sodium-Glucose Co-Transporter-2 Inhibitors and Cardiac Outcomes Among Patients Treated With Anthracyclines.
    Gongora CA; Drobni ZD; Quinaglia Araujo Costa Silva T; Zafar A; Gong J; Zlotoff DA; Gilman HK; Hartmann SE; Sama S; Nikolaidou S; Suero-Abreu GA; Jacobsen E; Abramson JS; Hochberg E; Barnes J; Armand P; Thavendiranathan P; Nohria A; Neilan TG
    JACC Heart Fail; 2022 Aug; 10(8):559-567. PubMed ID: 35902159
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sodium-glucose co-transporter-2 inhibitors in type 2 diabetes: Are clinical trial benefits for heart failure reflected in real-world clinical practice? A systematic review and meta-analysis of observational studies.
    Hinton W; Ansari AS; Whyte MB; McGovern AP; Feher MD; Munro N; de Lusignan S
    Diabetes Obes Metab; 2023 Feb; 25(2):501-515. PubMed ID: 36239122
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Contemporary use of SGLT2 inhibitors in heart failure patients with diabetes mellitus: a comparison of DPP4 inhibitors in a nationwide electric health database of the superaged society.
    Nakai M; Iwanaga Y; Kanaoka K; Sumita Y; Nishioka Y; Myojin T; Kubo S; Okada K; Soeda T; Noda T; Sakata Y; Imamura T; Saito Y; Yasuda S; Miyamoto Y
    Cardiovasc Diabetol; 2022 Aug; 21(1):157. PubMed ID: 35964039
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sodium Glucose Co-transporter 2 Inhibitors and Heart Failure.
    Ghosh RK; Ghosh GC; Gupta M; Bandyopadhyay D; Akhtar T; Deedwania P; Lavie CJ; Fonarow GC; Aneja A
    Am J Cardiol; 2019 Dec; 124(11):1790-1796. PubMed ID: 31627834
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sodium-glucose co-transporter 2 inhibitors in heart failure: beyond glycaemic control. A position paper of the Heart Failure Association of the European Society of Cardiology.
    Seferović PM; Fragasso G; Petrie M; Mullens W; Ferrari R; Thum T; Bauersachs J; Anker SD; Ray R; Çavuşoğlu Y; Polovina M; Metra M; Ambrosio G; Prasad K; Seferović J; Jhund PS; Dattilo G; Čelutkiene J; Piepoli M; Moura B; Chioncel O; Ben Gal T; Heymans S; de Boer RA; Jaarsma T; Hill L; Lopatin Y; Lyon AR; Ponikowski P; Lainščak M; Jankowska E; Mueller C; Cosentino F; Lund L; Filippatos GS; Ruschitzka F; Coats AJS; Rosano GMC
    Eur J Heart Fail; 2020 Sep; 22(9):1495-1503. PubMed ID: 32618086
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of sodium glucose co-transporter inhibitors in heart failure prevention.
    Garla V; Subauste A; Butler J; Lien LF
    J Diabetes Complications; 2021 Mar; 35(3):107811. PubMed ID: 33280983
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sodium-glucose co-transporter-2 inhibitors eligibility in patients with heart failure with reduced ejection fraction.
    Monzo L; Ferrari I; Cicogna F; Tota C; Calò L
    Int J Cardiol; 2021 Oct; 341():56-59. PubMed ID: 34454968
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biomolecular Mechanisms of Cardiorenal Protection with Sodium-Glucose Co-Transporter 2 Inhibitors.
    Prandi FR; Barone L; Lecis D; Belli M; Sergi D; Milite M; Lerakis S; Romeo F; Barillà F
    Biomolecules; 2022 Sep; 12(10):. PubMed ID: 36291558
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Mechanism of Astragali Radix-Puerariae Lobatae Radix combination in regulating type 2 diabetes mellitus through AMPK signaling pathway: based on network pharmacology and experimental verification].
    Wei S; Li J; Han DW; Fu Q; Hao F
    Zhongguo Zhong Yao Za Zhi; 2022 May; 47(10):2738-2749. PubMed ID: 35718494
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Renal and Cardiovascular Effects of sodium-glucose cotransporter 2 (SGLT2) inhibition in combination with loop Diuretics in diabetic patients with Chronic Heart Failure (RECEDE-CHF): protocol for a randomised controlled double-blind cross-over trial.
    Mordi NA; Mordi IR; Singh JS; Baig F; Choy AM; McCrimmon RJ; Struthers AD; Lang CC
    BMJ Open; 2017 Oct; 7(10):e018097. PubMed ID: 29042392
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Role of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Heart Failure, Regardless of Diabetes Status: Focus on Cardiovascular Disease.
    Ferrari F; Martins VM; Scheffel RS; da Silveira AD; Motta MT; Moriguchi EH; Santos RD; Stein R
    Ann Pharmacother; 2021 Oct; 55(10):1267-1275. PubMed ID: 33401940
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Therapeutic mechanism of
    Zhao Y; Zhao X; Zhu Q; Zhu B; Zhang Z; Chen J
    Nan Fang Yi Ke Da Xue Xue Bao; 2023 May; 43(5):772-782. PubMed ID: 37313819
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.